

Data collection	Est. number of respondents	Responses per respondent	Burden per response *	Total annual burden hrs.
Application to Medical Staff .....	600	1	1.00 (60 mins) ....	600.0
Reference Letter .....	1800	1	0.33 (20 mins) ....	594.0
Reappointment Request .....	200	1	1.00 (60 mins) ....	200.0
Ob-Gyn Privileges .....	25	1	1.00 (60 mins) ....	25.0
Internal Medicine .....	387	1	1.00 (60 mins) ....	387.0
Surgery Privileges .....	23	1	1.00 (60 mins) ....	23.0
Psychiatry Privileges .....	18	1	1.00 (60 mins) ....	18.0
Anesthesia Privileges .....	16	1	1.00 (60 mins) ....	16.0
Dental Privileges .....	128	1	0.33 (20 mins) ....	42.2
Optometry Privileges .....	21	1	0.33 (20 mins) ....	6.9
Psychology Privileges .....	23	1	0.17 (10 mins) ....	3.9
Audiology Privileges .....	6	1	0.08 (5 mins) .....	0.48
Podiatry Privileges .....	6	1	0.08 (5 mins) .....	0.48
Radiology Privileges .....	9	1	0.33 (20 mins) ....	2.9
Pathology Privileges .....	3	1	0.33 (20 mins) ....	.99
<b>Total .....</b>	<b>3,265</b>			<b>1,920.85</b>

\*For ease of understanding, burden hours are provided in actual minutes.

There are no capital costs, operating costs and/or maintenance costs to respondents.

*Request for Comments:* Your written comments and/or suggestions are invited on one or more of the following points: (a) Whether the information collection activity is necessary to carry out an agency function; (b) whether the agency processes the information collected in a useful and timely fashion; (c) the accuracy of public burden estimate (the estimated amount of time needed for individual respondents to provide the requested information); (d) whether the methodology and assumptions used to determine the estimate are logical; (e) ways to enhance the quality, utility, and clarity of the information being collected; and (f) ways to minimize the public burden through the use of automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

*Send Comments and Requests for Further Information:* For the proposed collection or requests to obtain a copy of the data collection instrument(s) and instructions to: Mrs. Christina Rouleau, IHS Reports Clearance Officer, 801

Thompson Avenue, TMP Suite 450, Rockville, MD 20852, call non-toll free (301) 443-5938, send via facsimile to (301) 443-2316, or send your e-mail requests, comments, and return address to: [crouleau@hqe.ihs.gov](mailto:crouleau@hqe.ihs.gov).

*Comment Due Date:* Your comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

Dated: June 15, 2006.

**Robert G. McSwain,**

*Deputy Director, Indian Health Service.*

[FR Doc. 06-5574 Filed 6-21-06; 8:45 am]

**BILLING CODE 4165-16-M**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Government-Owned Inventions; Availability for Licensing**

**AGENCY:** National Institutes of Health, Public Health Service, HHS.

**ACTION:** Notice.



**SUMMARY:** The inventions listed below are owned by an agency of the U.S.

Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of Federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**ADDRESSES:** Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

**Beta-Amyloid PET Imaging Agents**

*Description of Technology:* Available for licensing and commercial development are two novel classes of compounds useful as radioligands for *in vivo* imaging of beta-amyloid (A $\beta$ ) peptides and plaques in humans.



Beta-amyloid peptide deposition in the brain is a pathological feature of Alzheimer's disease (AD). Early detection of beta-amyloid load in patients with suspected AD is vital to initiating early treatment, which can improve cognitive function and quality of life for many patients.

The invention describes novel derivatives of imidazopyridinylbenzeneamine (IMPY) and benzothiazolylbenzeneamine (BTA), which demonstrate high *in vitro* binding affinity to human beta-amyloid. The difference between existing IMPY compounds and the novel derivatives is the substitution of an aryl halide with an aryl thioether group and replacement of a sulfur group of the pyridine ring with a nitrogen group. The new classes of compounds have the potential of providing improved amyloid imaging agents for Positron Emission Tomography (PET) with higher specificity for amyloid, low background noise, better entry into the brain and improved labeling efficiency.

In addition to the novel compounds, the invention also includes: (1) A new method of synthesizing the IMPY derivatives, using palladium as a catalyst, (2) methods of imaging beta-amyloid deposits in the brain by *in vivo* PET, magnetic resonance imaging (MRI) and other imaging methods involving the use of these compounds, and (3) and methods of labeling these compounds with radiotracers ([11-C] and [18-F]).

**Inventors:** Lisheng Cai (NIMH), Victor Pike (NIMH), and Robert Innis (NIMH).

#### Publications:

1. Nichols L, Pike VW, Cai L, Innis RB. (2006) "Imaging and In Vivo Quantitation of beta-Amyloid: An Exemplary Biomarker for Alzheimer's Disease?," *Biol Psychiatry*. [E-pub ahead of print].

2. Toyoma H, et al. (2006) "PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease," *Eur J Nucl Med Mol Imaging*. 32(5), 593-600.

3. Cai L, et al. (2004) "Synthesis and Evaluation of Two<sup>18</sup>F-Labeled 6-Iodo-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridine Derivatives as Prospective Radioligands for -Amyloid in Alzheimer's Disease," *J Med Chem*, 47 (9), 2208-2218.

**Patent Status:** U.S. Provisional Application filed 21 Apr 2006 (HHS Reference No. E-156-2006/0-US-01).

**Licensing Status:** Available for non-exclusive or exclusive licensing.

**Licensing Contact:** Michael Shmilovich; 301/435-5019; [shmilovm@mail.nih.gov](mailto:shmilovm@mail.nih.gov).

**Collaborative Research Opportunity:** The NIMH Molecular Imaging Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Beta-Amyloid PET Imaging Agents. Please contact Suzanne Winfield at [winfiels@mail.nih.gov](mailto:winfiels@mail.nih.gov) for more information.

#### Carbohydrate-Encapsulated Quantum Dots for Cell-Specific Biological Imaging

**Description of Technology:** Available for licensing is intellectual property covering carbohydrate-encapsulated quantum dots (QD) for use in medical imaging and methods of making the same. Certain carbohydrates, especially those included on tumor glycoproteins are known to have affinity for certain cell types. One notable glycan used in the present invention is the Thomsen-Freidenreich disaccharide (Galb1-3GalNAc) that is readily detectable in 90% of all primary human carcinomas and their metastases. These glycans can be exploited for medical imaging. Quantum Dots (QDs) are semiconductor nanocrystals (CdSe or CdTe) with detectable luminescent properties. Encapsulating luminescent QDs with target-specific glycans permits efficient imaging of the tissue to which the glycans bind with high affinity. Accurate imaging of diseased cells (e.g., primary and metastatic tumors) is of primary importance in disease management. The inventors describe a method for enhancing the luminescence of carbohydrate-encapsulated QDs by addition of specific functional units in a novel synthesis of hybrid CdTe-based core-shell semiconductor nanocrystals.

**Inventors:** Joseph Barchi and Sergey Svarovsky (NCI).

**Patent Status:** PCT Application No. PCT/US03/34897 filed 05 Nov 2003 (HHS Reference No. E-325-2003/0-PCT-01).

*Licensing Status:* Available for non-exclusive or exclusive licensing.

*Licensing Contact:* Michael Shmilovich; 301/435-5019; [shmilovm@mail.nih.gov](mailto:shmilovm@mail.nih.gov).

*Collaborative Research Opportunity:* The National Cancer Institute, Center for Cancer Research, Laboratory of Medicinal Chemistry is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize carbohydrate-encapsulated quantum dots. Please contact Dr. Melissa Maderia by phone: (301) 846-5465 or fax: (301) 846-6820 or e-mail: [maderiam@mail.nih.gov](mailto:maderiam@mail.nih.gov) for more information.

Dated: June 14, 2006.

**David R. Sadowski,**

*Acting Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 06-5579 Filed 6-21-06; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Mental Health; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Mental Health Special Emphasis Panel, HIV and Psychiatric Comorbidities.

*Date:* July 10, 2006.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

*Contact Person:* Peter J. Sheridan, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6142, MSC 9606, Bethesda, MD 20892-9606. 301-443-1513. [psherida@mail.nih.gov](mailto:psherida@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS)

Dated: June 14, 2006.

**Anna Snouffer,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 06-5571 Filed 6-21-06; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Electrical Signaling, Ion Transport, and Arrhythmias Study Section, June 22, 2006, 8 a.m. to June 23, 2006, 5 p.m., Georgetown Suites, 1111 30th Street, NW., Washington, DC 20007 which was published in the **Federal Register** on May 11, 2006, 71 FR 27505-27507.

The meeting will be held at the Georgetown Suites, 1000 29th Street, NW., Washington, DC 20007. The meeting dates and time remain the same. The meeting is closed to the public.

Dated: June 13, 2006.

**Anna Snouffer,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 06-5572 Filed 6-21-06; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant

applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Psychiatric Genetics Collaborative R01's

*Date:* June 30, 2006.

*Time:* 2 p.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* The Watergate, 2650 Virginia Avenue, NW., Washington, DC 20037.

*Contact Person:* Cheryl M. Corsaro, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2204, MSC 7890, Bethesda, MD 20892, (301) 435-1045, [corsaroc@csr.nih.gov](mailto:corsaroc@csr.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Bacterial Vaginosis—A Clinical Study.

*Date:* June 30, 2006.

*Time:* 3 p.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Robert Freund, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3200, MSC 7848, Bethesda, MD 20892, 301-435-1050, [freundr@csr.nih.gov](mailto:freundr@csr.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, EMNR Special Emphasis Panel SBIR.

*Date:* July 6-7, 2006.

*Time:* 7 p.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Krish Krishnan, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6164, MSC 7892, Bethesda, MD 20892, (301) 435-1041, [krishnak@csr.nih.gov](mailto:krishnak@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Review of Member Conflict Applications.

*Date:* July 7, 2006.

*Time:* 1 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* St. Gregory Hotel, 2033 M Street, NW., Washington, DC 20036.

*Contact Person:* Mark P. Rubert, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5218, MSC 7852, Bethesda, MD 20892, 301-435-1775, [rubertm@csr.nih.gov](mailto:rubertm@csr.nih.gov).

*Name of Committee:* AIDS and Related Research Integrated Review Group, AIDS